What questions can my attending ask when presenting a Systemic Lupus Erythematosus (SLE) case?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Key Questions Your Attending May Ask When Presenting an SLE Case

Your attending will likely focus on questions that assess disease activity, organ involvement, and management strategies to minimize morbidity and mortality in SLE patients. 1

Disease Characteristics and Diagnosis

  • What classification criteria does this patient meet for SLE diagnosis?
  • What was the patient's initial presentation and how has the disease evolved?
  • What is the current ANA titer and pattern? (Remember titers ≥1:640 or specific patterns like nuclear homogeneous have stronger associations with autoimmune diseases) 2
  • What specific autoantibodies are present? (anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, anti-phospholipid) 1
  • Are complement levels (C3, C4) decreased, suggesting active disease? 1

Organ System Involvement

Mucocutaneous

  • How would you characterize the skin lesions? Are they LE-specific, LE-nonspecific, LE mimickers, or drug-related? 1
  • Have you assessed skin activity and damage using validated indices like CLASI? 1

Renal

  • What is the patient's renal function (creatinine, eGFR, urinalysis, protein/creatinine ratio)? 1
  • Is there evidence of lupus nephritis? If so, what class? 3
  • If nephritis is present, how frequently are you monitoring renal parameters? (Should be at least every 3 months for the first 2-3 years) 1

Neuropsychiatric

  • Are there any neuropsychological symptoms (seizures, paresthesias, numbness, weakness, headache, depression)? 1
  • Have you assessed for cognitive impairment (attention, concentration, memory, word finding difficulties)? 1

Other Systems

  • What other organ systems are affected (hematologic, cardiovascular, pulmonary, gastrointestinal)?
  • For patients on antimalarials or glucocorticoids: When was the last eye examination? 1

Disease Activity and Monitoring

  • What laboratory tests are you monitoring and at what intervals? 1
  • What is the current disease activity status (remission, low activity, or active disease)? 3
  • What validated disease activity index are you using (SLEDAI, BILAG, etc.)?
  • What damage has accumulated (SLICC Damage Index)?

Treatment Plan

  • Is the patient on hydroxychloroquine? (Standard of care associated with reduced mortality) 3
  • What is the current glucocorticoid dose and what is your plan to minimize it? 4
  • What immunosuppressive agents are being used and why were they selected? 3
  • Have you considered biologic therapies like belimumab for active disease? 5, 3
  • For lupus nephritis: Have you considered newer approved therapies like voclosporin? 3

Complications and Comorbidities

  • What preventive measures are in place for cardiovascular disease? 2
  • What is the patient's infection risk and vaccination status? 4
  • Is the patient at risk for osteoporosis? What preventive measures are in place? 4
  • For female patients: What is the pregnancy plan and contraception status? (Especially important with anti-Ro/La antibodies or antiphospholipid antibodies) 1, 2

Patient Education and Adherence

  • What lifestyle modifications have been recommended (UV protection, smoking cessation)? 6
  • How is the patient's medication adherence, particularly to hydroxychloroquine? 4
  • What is the patient's understanding of their disease and treatment plan?

Common Pitfalls to Avoid

  • Don't rely solely on laboratory values to assess disease activity; clinical assessment is equally important
  • Don't attribute all symptoms to SLE without ruling out other causes
  • Don't forget to monitor for drug toxicities (e.g., antimalarial retinopathy, glucocorticoid side effects)
  • Don't overlook the importance of hydroxychloroquine as the cornerstone of SLE therapy 3
  • Don't miss the opportunity to screen for and prevent comorbidities that contribute to morbidity and mortality

By anticipating these questions and preparing comprehensive answers, you'll demonstrate a thorough understanding of SLE management that prioritizes reducing morbidity and mortality while improving quality of life for your patient.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Autoimmune Disease Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Systemic lupus erythematosus.

Lancet (London, England), 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.